Scientific Advisors

Ali Al-Hakim Doctor

Ali Al-Hakim,Ph.D., Postdoctoral Research Associate, University of East Anglia, United Kingdom, former Director of the FDA's New Drug Review Division.

Ali Al-Hakim doctor is a heparin expert of the United States FDA, and has handled the registration and approval of all heparin drugs since joining the FDA in 1994. He is an authoritative figure in the heparin drug field, published more than 30 research papers in internationally renowned journals, and participated in many international conferences and published important opinions. During his work in the United States FDA, he was honored by the FDA many times for his outstanding contributions.

In 2022, Dr. Ali Al-Hakim retired from the FDA and received the Distinguished Career Service Award from the FDA. After retirement, he joined Suzhou Ronnsi Pharma Co., Ltd. as a consultant.

Jawed Fareed Doctor, Professor

Jawed Fareed received his Ph.D. degree of Pharmacology & Therapeutics from Loyola University Chicago and his MS from University of London, Imperial College of Technology. He also received the degree of Doctor Honoris Causa from various national and international universities. Dr. Fareed is a professor of Pathology and Laboratory Medicine, Molecular Pharmacology and Neurociences. He is also a fellow of American Heart Association (FAHA) , a member of FDA heparin group, a fellow and consultant of FDA.

Dr. Jawed Fareed is an internationally renowned expert of heparin with more than 50 years’ experience. He specializes in theoretical research of low molecular weight heparin and promoted the research and development of a variety of anticoagulant and antithrombotic drugs. Dr. Fareed has served as the Secretary-General of the International Society for Angiography (IUA), Vice Chairman of the North American Thrombosis Forum, and the South Asian Society of Atherosclerosis and Thrombosis (SASAT). He has served as a consultant of United states Pharmacopeia (USP), a consultant of Food and Drug Administration (FDA), National Institute of Health (NIH). He has published over 600 peer-reviewed manuscripts.

Dr. Jawed Fareed joined Suzhou Ronnsi Pharma Co., Ltd as the chief technical consultant in 2016.

Shaker A. Mousa Doctor, Professor

Shaker A. Mousa,Doctor of the Ohio State University College of Medicine, Professor at Rensselaer Polytechnic Institute, Adjunct Professor at the State University of New York at Albany, the State University of New York at Buffalo and Temple University, Visiting Professor of Bioethics at Albany Medical College, MBA (MBA), Member of FACC (American College of Cardiology) and FACB (American Society of Clinical Biochemistry).

Shaker A. Mousa He was appointed tenured Professor, Executive Vice President and Chairman of the Institute of Pharmacy (PRI) at Rensselaer Polytechnic Institute in 2002, and Vice President for Research and Development at the Albany School of Pharmacy and Health Sciences in 2010. Earlier in his career, Dr. Shaker A. Mousa spent 17 years as A senior scientist and researcher at DuPont Pharmaceutical Company, where he served as a team leader for several drug development programs from 1993 to 2001. Dr. Shaker A. Mousa's research efforts focus on the diagnosis and treatment of angioplastic diseases, thrombotic diseases, and endovascular diseases, and he has published more than 500 research papers and holds more than 350 U.S. and international patents.

In 2017, Dr. Shaker A. Mousa became A consultant of Suzhou Ronnsi Pharma Co., Ltd.

Robert J. Linhardt Doctor, Professor

Robert J. Linhardt received his Ph.D. degree from the Johns Hopkins University. He is a Professor of Biocatalysis and Metabolic Engineering at Rensselaer Polytechnic Institute, holding joint appointments in the Departments of Chemistry and Chemical Biology, Biology, Chemical and Biological Engineering, and Biomedical Engineering. He is a fellow and consultant of FDA, a fellow of the National Academy of Inventors (NAI), a fellow of the AAAS, and one of the Scientific American Top 10.

Dr. Linhardt is an internationally renowned expert of bioactive sugars, particularly heparin. He is an editorial board member of “Journal of Biological Chemistry”, “Applied Biochemistry and Biotechnology” and “Journal of Carbohydrate Chemistry”. He has published over 500 peer-reviewed manuscripts and holds over 40 patents.

Choon Teo Shareholder/Consultant

Choon Teo received his Master of Chemical Engineering from University of Oklahoma. Then he joined various global leading companies as senior engineer and executive, and accumulated rich R&D experience and global management experience. Previously he has served in Sagent (Asian), Pfizer (New York and Singapore), Bayer. He also served as CEO of pharmaceutical factory with an investment of 300 million US dollars in Greenfield.

With his great contribution, multiple pharmaceutical projects successfully passed FDA audit in the United States, Singapore and India. During the construction of the factory in Nanjing, Heparin sodium API was approved by the FDA.

He was appointed as deputy chairman of the board, Vice President, General manager in Zhejiang pharmaceutical co. in 2013. He took stakes of Ronnsi and joined as shareholder and consultant in 2021.

Steve Yang Shareholder/Consultant

Steve Yang, B.S. in Chemistry from the University of California, Berkeley and Ph.D. in Biology from the Massachusetts Institute of Technology, is the CEO of PT Metiska.

Dr. Steve Yang, winner of the Glenn T.Seaborg Research Excellence Award, is the Principal Scientist of the Solid Tumors Program at Mochtar Riady Comprehensive Cancer Center, Indonesia, Director of OH2 Laboratories (Cambridge, MA), USA, Director of vNeu Teknologi, Indonesia, and Director of the Company. Co-founder and director of Onco Network, Indonesia; Senior advisor of Alpha JWC Venture Capital, Indonesia fund; former management consultant of McKinsey & Company.

In 2017, Dr. Steve Yang invested in Suzhou Ronnsi Pharma Co., Ltd. and became a shareholder and consultant of the company. As a shareholder with Indonesian background, responsible for the declaration of heparin products in Indonesia and the development of the Indonesian market.

CuiHua Liu

Chloe Liu Shareholder/Consultant

Cuihua (Chloe) Liu received her PhD in Biophysical Chemistry from the University of Western Ontario, Canada, and completed her postdoc training in Genetic structural biology at the University of Massachusetts at Amherst, USA. She is one of the leading talents in innovation and entrepreneurship in Guangzhou and Pearl River delta.

Dr. Liu currently is Senior Vice President of Bio-Thera Solutions, leading and managing CMC development. She has over 20 years of biotech and biopharmaceutical industry experience and experience of 2 startups. Previously, Dr. Liu served as technical leader, CTO and executive in Pfizer, Momenta (now J&J), Biomabs, Huaota, Alphamab, and Hepalink. She also has rich experience in R&D system construction and project management in an international environment. She set up and developed internationalization strategy for various biotech and biopharmaceutical companies. Dr. Liu has led and managed CMC development for more than 50 complex mixture products of non-biologics and biologics across the IND phases, several of which have obtained US, EU and China marketing approvals. Dr. Liu has published over 20 peer-reviewed manuscripts and holds over 10 patents

Dr. Liu took stakes of Ronnsi and joined Ronnsi as shareholder and consultant in 2017.